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Objectives: The Lack of Adherence to Immunosuppressive Treatment (LAIT) 
has been associated with Chronic Humoral Rejection (CHR) and decreased graft 
survival which can increase Health Resource Utilisation (HRU). Prevalence of 
LAIT has been reported to range between 7.4% and 41.8% of Spanish Kidney 
Transplant (KT) patients and published studies suggest LAIT may cause up to 
20-50% of CHR episodes in Spain. The objective of this study was to estimate the 
resource utilization associated with LAIT in KT patients in Spain. MethOds: 
A systematic literature review was conducted using Medline, PsycINFO and 
BVS to identify Spanish studies published between 2009 and 2013 focusing on 
KT and LAIT. Following the review a questionnaire was developed to explore 
HRU associated with LAIT. Six national experts in KT from Spain completed 
the survey and the data was analyzed using Computer Assisted Qualitative 
Data Analysis (CAQDAS). HRU was estimated independently for suspected 
LAIT, suspected CHR, confirmed CHR and graft loss. Results: Suspected LAIT 
and CHR were associated with additional HRU quantified by additional neph-
rologist visits, heightened immunosuppressive blood-level monitoring, and 
2 measurements of anti-HLA antibodies (Luminex), 1 ultrasound scan and 1 
kidney biopsy. Confirmed CHR was associated with additional HRU such as 
increases in the number of follow-up visits from 1 visit every 4-6 months to 1 
visit every 1-2 months, associated monitoring and testing (bloods, ultrasonog-
raphy, donor-specific antibodies, proteinuria). A proportion of these patients 
are treated with intravenous immunoglobulin, rituximab and plasmapheresis, 
and kidney biopsy to check whether CHR is resolved. Finally, most CHR epi-
sodes, up to 60%, cause graft loss with increased HRU associated with intensive 
patients’ follow-up to prepare the return to dialysis and renal replacement ther-
apy. cOnclusiOns: The lack of adherence to immunosuppressive treatment 
may lead to CHR and graft loss with an associated increase of healthcare resource 
utilization.
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Objectives: To study the utility of SSU rRNA and COWP gene PCR-RFLP for the 
detection of C. parvum, C. hominis, C. meleagridis, and C. andersoni. MethOds: 
845 stool samples from 323 patients in renal transplant (RT) recipients and 50 
healthy controls between January 2006 and August 2011 were examined for 
Cryptosporidium by Modified acid-fast (Kinyoun’s) staining technique. DNA was 
extracted and was subjected to PCR-RFLP for species detection in cases positive for 
Cryptosporidium by microscopy. Results: Cryptosporidium was detected more 
commonly among the RT recipients than healthy controls (23/323, vs. 0/50, respec-
tively; p= 0.005). All the Cryptosporidium positive cases (23/23) were detected using 
the PCR-RFLP of SSU rRNA gene, 15/23 were C. hominis and 8/23 were C. parvum. 
Only 17/23 cases were detected by COWP genes of which 9/17 were C. hominis 
and 8/17 were C. parvum. By comparing the SSU & COWP gene PCR-RFLP with 
microscopy as the gold standard, SSU gene PCR-RFLP proved to be more sensitive 
& specific (100%) than COWP (sensitivity & specificity of COWP PCR-RFLP was 
73.9% and 100% respectively). C. meleagridis and C. andersoni were not detected 
in any case. cOnclusiOns: Cryptosporidiosis is a common cause of diarrhea 
in RT recipients. The most common species was Cryptosporidium hominis. SSU 
rRNA PCR-RFLP is more suitable for identification of Cryptosporidium species 
than COWP.
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Objectives: To prioritize comparative effectiveness research (CER) questions to 
improve home dialysis practice using a multicriteria decision analysis (MCDA) 
framework. MethOds: Candidate CER questions (n= 13) were generated and 
refined in PICO format by an international network of nephrologists (n= 28) 
using a nominal group process. The EVIDEM framework was adapted to include 
11 criteria to assess the value of these research questions to improve prac-
tice from a holistic standpoint, including the impact, context and outcomes of 
the CER question, feasibility of study, economics and implementation of study 
findings. Quality of evidence to be generated was also included as a criterion, 
with consideration of 13 subcriteria outlining the risk of bias and precision. 
First, participants were asked to weight each criterion independently of the 
research questions. Second, for each research question, participants assigned a 
score for each criterion. Average overall values of CER questions were obtained 
by combining weights and scores using a linear model. Results: Participants 
assigned highest importance to the following criteria: Impact on patient sur-
vival and other major clinical outcomes, Unmet needs, and Feasibility of the 
CER question. Value of CER questions varied between 48% and 73% of maximum 
value on the MCDA scale. Highest value estimates (> 70%) were obtained for 
research questions exploring the association between vascular access or dialysis 
selection process and mortality/morbidity. Ranking had excellent face validity 
for all criteria. Results of this ranking process were used to prioritize research 
planning for the international network of nephrologists. cOnclusiOns: 
Holistic MCDA provides a useful tool for comparative effectiveness 
research to ensure prioritization of CER questions with highest benefits 
for improving clinical practice, as illustrated by this application for home 
dialysis.
The medication adherence rate scores of the patients at academic hospital 
(4.35 ± 1.31), corporate hospital (4.38 ± 1.10) and government hospital (4.16 ± 
1.28). cOnclusiOns: The overall mean medication adherence rate score of the 
patients is 4.34 ± 1.23 and there is no significant difference in mean scores among 
hemodialysis centres (p 0.722). The health care professionals need to educate the 
patients about their disease state and importance of adherence to prescribed 
medications.
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Objectives: This study aimed to build a conceptual framework in patients with IC/
PBS which is a chronic debilitating condition characterized by pelvic pain, urinary 
urgency, and urinary frequency. It affects around 0.7-1 million people in the US and 
mostly middle aged women. Diagnostic criteria developed for research are not effi-
cient and missing 60% of all cases. Uncertainty surrounds definition, etiology, diag-
nosis, natural history, true prevalence, and most effective treatment(s). MethOds: 
Literature review results were used to design semi-structured telephone inter-
views to elicit concepts of importance for IC/PBS patients on functioning and life. 
Interviews were held with clinical experts and UK patients until saturation of 
concepts. Transcripts were analyzed thematically. Results: Two clinical experts 
and 30 female patients were interviewed. IC/PBS was defined as a chronic pain 
syndrome that may begin as a pathologic process in the bladder in most (but not 
all) patients. Pain and frequency were reported as the most bothersome symptoms. 
Relationships, activities, energy levels, and psychological impact were reported to 
be the key areas of impact. ‘Not being able to do what I used to’ , ‘worry about toilet 
access’ , ‘impact on work life’ , and ‘impact on family / home life’ were mentioned as 
having the greatest impact. A broad range of treatments was reported with a broad 
range of treatment side effects. The experts’ results contributed the following: pain 
drives frequency and younger people report a heavier burden. cOnclusiOns: The 
conceptual framework of this study contributes to the understanding of IC/PBS. IC/
PBS has a profound and debilitating effect on all aspects of patients’ lives, from 
preventing them to work over participating in family life and traveling to being 
house-bound with greatly impacted change in roles and self-perceptions, lead-
ing to feelings of being ‘not-normal’ causing anxiety, depression and even suicidal 
tendencies.
Urinary/Kidney diSorderS – health Care Use & Policy Studies
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Objectives: The medical management of men with Lower Urinary Tract 
Symptoms often involves agents targeting bladder outlet obstruction (BOO) such 
as α -blockers or 5-α reductase inhibitors (5ARI). However, overactive bladder 
(OAB) symptoms may coexist with BOO. This study aims to describe the base-
line characteristics of men who utilize OAB [mirabegron and antimuscarinics 
(AM)] therapy and sequential and combination use of various urologic medica-
tion classes. MethOds: Data from a US commercial database were analyzed for 
men starting OAB therapy between 10/01/12 and 12/31/13. Men were grouped by 
initiation of mirabegron or AM. A 12-month retrospective analysis was conducted 
with patients defined as naïve or experienced to AM therapy 12-month period 
prior to index. Baseline demographics and comorbid conditions were compared. 
Concomitant BOO medications, in use at baseline, initiated, or discontinued during 
the 90 days pre/post index date of mirabegron or AM, were analyzed. Results: 
More men on mirabegron saw a urologist (75% vs 35%), more likely to have BOO 
diagnosed (66% vs 49%) and use in free combination with α -blockers (26% vs 17%) 
and 5ARI (7% vs 4%) therapy versus AM. Baseline characteristics showed mira-
begron patients were older (64 vs 59) and had a higher Elixhauser comorbidity 
index (4.7 vs 4.0) compared with AM patients. Baseline health resource utiliza-
tion (HRU) was higher among the mirabegron cohort for urodynamic (58% vs 
29%), cystoscopy (25% vs 19%), polypharmacy (10.4 vs. 8.2) and overall outpatient 
visits (11.4 vs 8.5). More mirabegron patients had prior prostate (7.6% vs 5.8%) 
and OAB (3.9% vs 0.7%) surgical therapy 12-months prior to index compared to 
AM patients. cOnclusiOns: Male patients receiving mirabegron showed dis-
tinct baseline characteristics. Patients managed by urologists were often more 
complicated with greater baseline HRU. Additional studies to model the impact 
of patient characteristics on outcomes in those prescribed mirabegron and AMs 
may be helpful.
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biloba, and pycnogenol. Half of the studies focused on breast cancer. Most resulted in 
statistically non-significant findings, but two studies of erythpoietin and the pycnog-
enol trial had significant results. All 3 of the non-pharmacological studies focused on 
patients with breast cancer, two using a form of cognitive-behavior therapy (CBT) and 
the third studying a yoga program. cOnclusiOns: The review found a large number 
of studies documenting the problem of CRCD, discussing innovative ways of measur-
ing the extent of the cognitive impairment, and describing etiological theories, such 
as the relationship of CRCD to fatigue and anemia. However, there was a paucity of 
well-designed, sufficiently powered studies of potential treatments, given the extent 
of the problem and its impact on patient functioning. This is an area of clear patient 
need which warrants further scientific study.
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hyPofraCtioned radiotheraPy in the treatment of early BreaSt 
CanCer: SyStematiC review and meta-analySiS
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Objectives: To evaluate short and long term effects of hypofractioned radiation 
therapy in women with early stage breast cancer, after undergoing breast con-
servative surgery. MethOds: We searched for randomized controlled trials in 
Embase, Medline, Cochrane Library and Lilacs comparing unconventional versus 
conventional fractioning. The authors performed data extraction independently. 
Disagreements were resolved by consensus. Random-effects risk ratios (RR) were 
calculated comparing patients randomized to unconventional with those to con-
ventional fractioning. Periods before and after five years of treatment were consid-
ered. Results: Five trials reported on 7.802 women. The studies were of medium to 
high quality. Unconventional fractionation did not affect, until five years and after 
five years, respectively: (1) local recurrence RR 0.90 (95% CI 0.68 to 1.18, P = 0.44) and 
RR 0.98 (95% CI 0.83 to 1.17, P = 0.86); (2) distant recurrence (RR) 1.04 (95% CI 0.73 to 
1.46, P = 0.84) and RR 1.02 (95% CI 0.79 to 1.32, P = 0.88); (3) mortality RR 0.89 (95% 
CI 0.77 to 1.05, P = 0.16) and RR 0.96 (95% CI 0.89 to 1.08, P = 0.48); (4) disease-free 
survival RR 0.96 (95% CI 0.78 to 1.18, P = 0.69) and RR 0.96 (95% CI 0.84 to 1.09, P = 
0.49); (5) cardiac ischemia RR 0.73 (95% CI 0.34 to 1.57, P = 0.42) and RR 0.61 (95% CI 
0.33 to 1.15, P = 0.13); (6) rib fracture RR 1.02 (95% CI 0.25 to 4.20, P = 0.98) and RR 1.08 
(95% CI 0.26 to 4.53, P = 0.91); (7) pulmonary fibrosis RR 2.42 (95% CI 0.50 to 11.71, 
P = 0.27) and RR 0.97 (95% CI 0.89 to 11.21, P = 0.07). cOnclusiOns: Using hypof-
ractioned radiotherapy regimens does not affect any of the outcomes analyzed in 
women with early stage breast cancer, after undergoing breast conservative surgery.
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Objectives: The purpose of this study was to estimate incidence of and identify fac-
tors associated with cardiotoxicity, defined as heart failure and/or cardiomyopathy, 
and all-cause mortality in breast cancer patients undergoing adjuvant chemotherapy 
or hormones. MethOds: A retrospective, population-based cohort study of 108,672 
women (≥ 66 years of age) newly diagnosed with breast cancer from 2001-2009 was 
conducted using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-
linked database. Adjuvant chemotherapy were classified as mutually exclusive 
groups: trastuzumab-based, anthracycline-based, anthracycline and trastuzumab-
based, taxane-based, and other chemotherapy. Propensity score matching adjusted for 
differences in patient characteristics across treatments. The final sample included a 
total of 11,250 women. Multivariable Cox proportional hazards regression models esti-
mated hazard ratios (HRs) of cardiotoxicity and all-cause mortality with adjustment 
for inverse probability weights, sociodemographics, cancer characteristics, comorbidi-
ties, surgery and radiation, region, and year at diagnosis. Results: Compared with 
hormones, risk of cardiotoxicity was higher in patients treated with anthracycline 
and trastuzumab-based (adjusted HR= 1.87; 95% confidence intervals [CI]= 1.51-2.33), 
trastuzumab-based (HR= 1.32; 95%CI= 1.14-1.52), and anthracycline-based (HR= 1.14; 
95%CI= 1.03-1.27) regimens, respectively. Certain baseline characteristics were sig-
nificant predictors of cardiotoxicity, including demographics (older age (vs. ≤ 70), 
non-Hispanic black), cancer characteristics (advanced stage), comorbidities (cardio-
vascular conditions or renal failure), year at diagnosis, and West region (vs. Northeast). 
Additionally, risk of all-cause mortality was higher in patients treated with taxane-
based (HR= 1.54; 95%CI= 1.43-1.67) regimens compared to hormones. Baseline charac-
teristics including sociodemographics, cancer characteristics, cardiovascular or renal 
failure comorbid conditions, year at diagnosis, and South region were significant pre-
dictors of all-cause mortality (all P< 0.05). cOnclusiOns: Women with breast cancer 
treated with trastuzumab-based and/or anthracycline-based regimens had increased 
cardiotoxicity risk compared with hormones, while those treated with taxane-based 
regimens had higher rates of all-cause mortality. Types of chemotherapy are associ-
ated with increased risk of cardiotoxicity and all-cause mortality. Practitioners should 
further evaluate treatment and patient characteristics for risk mitigation strategies.
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raCial/ethniCity diSParitieS in the aSSoCiation Between diaBeteS 
and PanCreatiC CanCer in the elderly mediCare PoPUlation
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Objectives: Although the relationship between diabetes and risk of pancreatic 
cancer are well-documented, limited research has examined whether racial/eth-
nicity differences accounted for the association between diabetes and pancreatic 
cancer. The aims of this study were to 1) assess whether diabetes is associated with 
pancreatic cancer in the elderly Medicare population, and 2) identify if any racial/
reSearCh PoSter PreSentationS - SeSSion iv
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CanCer – Clinical outcomes Studies
PCn1
Bone Safety Profile of denoSUmaB theraPy: a PharmaCoviGilanCe 
CharaCterization analySiS
Ali A.K.
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Objectives: Denosumab is a biologic approved in June 2010 to treat bone tumors 
and hypercalcemia of malignancy. This study characterizes bone-related safety sig-
nals of subtrochanteric atypical femoral fractures (SAF) and osteonecrosis of the 
jaw (ONJ) in relation to denosumab therapy. MethOds: The FDA Adverse Event 
Reporting System was used to detect signals of SAF and ONJ in relation to deno-
sumab therapy. Adverse event reports submitted between July 2010 and December 
2013 were retrieved and disproportional reporting of SAF and ONJ was calculated by 
Empirical Bayes Geometric Mean (EBGM). Denosumab-event pairs with EBGM 95% 
confidence interval lower limit ≥ 2.0 are considered signals of SAF and ONJ excess 
reporting compared to other drugs in the database. Events were defined by the 
Preferred Terms of the Medical Dictionary for Regulatory Activities, and denosumab 
was defined by the Anatomical Chemical Therapeutic Classification. Results: A 
total of 26,216 adverse event reports submitted for denosumab during the analysis 
period, corresponding to 30 for SAF and 721 for ONJ. Denosumab was significantly 
associated with more than expected reporting of SAF (EBGM= 17.5, 95%CI= 9.67-30.0) 
and ONJ (EBGM= 26.9, 95%CI= 20.1-35.9) compared to other drugs. The majority of 
denosumab users who experienced both events were females, and average age was 
69 years (SAF SD= 9.5; ONJ SD= 11.3). 12 SAF and 65 ONJ events lead to hospitaliza-
tion; 25 and 14 ONJ events contributed to patient disability and death, respectively. 
Other factors could have lead to these serious outcomes, including comedications 
and comorbidities. cOnclusiOns: SAF and ONJ are potential risks of denosumab 
therapy. Patients with thigh or hip pain should seek immediate medical help, and 
periodic dental and maxillofacial evaluations should be performed before and dur-
ing denosumab therapy. Pharmacoepidemiologic studies are recommended to fur-
ther characterize these risks, as some patients were treated with other medications, 
including systemic corticosteroids at the time of event occurrence.
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meta-analySiS of the Safety of SiPUleUCel-t immUnotheraPy in 
ProState CanCer
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Objectives: Sipuleucel-T is an autologous active cellular immunotherapy designed 
to reduce the risk of death in patients with prostate cancer. The aim of this study was 
to evaluate the safety of Sipuleucel-T for patients with prostate cancer. MethOds: 
PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were 
searched through January 10, 2015. Criteria for inclusion were randomized, pla-
cebo-controlled clinical trials on Sipuleucel-T, patients receiving three infusions, 
36 months follow-up and the availability of outcomes data for adverse events. The 
primary outcome was the total number of adverse events. Secondary outcomes 
examined eighteen specified adverse events. Two investigators selected studies 
independently and assessed the quality of studies using the Jadad scale. Point esti-
mates with a 95% confidence interval were generated. Fixed-effects or random 
random-effects models were based on the evaluation of heterogeneity. Results: 
Five clinical trials encompassing 1031 patients were included. The overall adverse 
events relative risk (RR) was 1.02 (95% CI 1.00 to 1.05, p= 0.091). For the secondary 
outcomes, differences were detected between Sipuleucel-T and placebo on chills (RR 
4.87; 95% CI 2.50 to 6.78, p= 0.000; 904 patients), fatigue (RR 1.20; 95% CI 1.01 to 1.43, 
p= 0.035; 1031 patients), pyrexia (RR 5.40; 95% CI 1.90 to 15.35, p= 0.002; 1031 patients), 
headache (RR 2.68; 95% CI 1.75 to 4.10, p= 0.000; 1031 patients), influenza like illness 
(RR 3.07; 95% CI 1.48 to 6.36, p= 0.003; 681 patients), myalgia (RR 2.24; 95% CI 1.26 
to 4.00, p= 0.006; 681 patients), nausea (RR 1.40; 95% CI 1.05 to 1.88, p= 0.023; 1031 
patients), vomiting (RR 1.86; 95% CI 1.21 to 2.88, p= 0.005; 856 patients) and dyspnea 
(RR 3.72; 95% CI 1.34 to 10.36, p= 0.012; 350 patients). cOnclusiOns: Sipuleucel-T 
significantly increased the risk of selected adverse events in patients with prostate 
cancer. Although many adverse events were transient, patients and providers should 
consider the potential risk of treatment with Sipuleucel-T.
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treatment for ChemotheraPy-related CoGnitive dySfUnCtion: 
review of the literatUre
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Objectives: Chemotherapy-related cognitive dysfunction (CRCD), colloquially known 
as ‘chemo fog’ or ‘chemo brain,’ describes the impact of chemotherapy on cogni-
tive functioning in domains ranging from memory to expressive language. CRCD is 
generally attributed to the direct or indirect effects of chemotherapy on the central 
nervous system, may occur at some level of intensity in as many as 75% of patients 
who have undergone chemotherapy, and impacts patient quality of life, educational/
occupational achievement, and social functioning. Management of CRCD includes 
both pharmacological and non-pharmacological therapies. MethOds: To better 
understand the range of treatments that have been studied for CRCD, and their rela-
tive efficacy, a comprehensive review of the published literature was undertaken. A 
MEDLINE search was conducted for relevant sources published in English between 
January 2005 and December 2014. The search was limited to studies describing tri-
als of interventions to manage or treat CRCD using non-pharmacological interven-
tions. Results: Of 161 records retrieved, 11 described interventions targeting CRCD. 
Pharmacological therapies used included erythropoietin, dexmethylphenidate, ginkgo 
